Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome  Florence Roufosse, MD, PhD, Aurore de Lavareille, PhD,

Similar presentations


Presentation on theme: "Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome  Florence Roufosse, MD, PhD, Aurore de Lavareille, PhD,"— Presentation transcript:

1 Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome 
Florence Roufosse, MD, PhD, Aurore de Lavareille, PhD, Liliane Schandené, PhD, Elie Cogan, MD, PhD, Ann Georgelas, MS, Lori Wagner, PhD, Liqiang Xi, MD, MS, Mark Raffeld, MD, Michel Goldman, MD, PhD, Gerald J. Gleich, MD, Amy Klion, MD  Journal of Allergy and Clinical Immunology  Volume 126, Issue 4, Pages e3 (October 2010) DOI: /j.jaci Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Phenotypically aberrant T-cell subsets detected by flow cytometry on whole blood from patients enrolled in the MHE trial. Phenotypically aberrant T-cell populations are shown within a closed shape (circle, box) on dot plots or are delimited by a horizontal bar (M1) on histograms. A, CD3-CD4+ cells (plot gated on total lymphocytes according to forward and side scatter). B, CD3-CD4+CD7- cells (histogram gated on CD3+CD4+ lymphocytes). C, CD3+CD4-(CD8+)CD5lo/- (plot gated on CD3+CD4- lymphocytes, which are mainly CD8+). D, CD3-CD4+CD8dim (plot gated on CD3+ lymphocytes). E, CD3-CD4dimCD8+ (plot gated on CD3+ lymphocytes). F, CD3+CD4+CD25hi (histogram gated on CD3+CD4+ lymphocytes). Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Superiority of mepolizumab over placebo in patients with L-HES. The response rate of patients with L-HES to mepolizumab versus placebo is shown; white bars represent the mepolizumab treatment arm, and hatched bars represent the placebo treatment arm. PDN, Prednisone; wk, week; Eos, blood eosinophil level. ∗P < .05; ∗∗P < For PDN 0 mg until end of study, 2-sided P value is .07 and 1-sided P value is .049 using the Fisher exact test. Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Histograms represent expression of surface antigens by normal CD3+CD4+ T cells (hashed line) and abnormal CD3-CD4+ T cells (filled or bold histograms) from patient 6 (Table I). Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome  Florence Roufosse, MD, PhD, Aurore de Lavareille, PhD,"

Similar presentations


Ads by Google